008 Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis

• Steve Vucic,
• Jeannette Lechner-Scott,
• Mark Slee,
• Suzanne Hodgkinson,
• Ernest Butler,
• Helmut Butzkueven,
• Michael Barnett,
• Richard Macdonell,
• Anneke Van Der Walt,
• Charles B Malpas,
• Pamela McCombe,
• Emmanuelle Leray,
• Sandra Vukusic,
• Izanne Roos,
• Katherine Buzzard,
• Olga Skibina

Affiliations

Steve Vucic

Westmead Clinical School, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia

Jeannette Lechner-Scott

University Newcastle, Newcastle, NSW, Australia

Mark Slee

1 Neurology, Flinders Medical Centre, Adelaide, South Australia, Australia

Suzanne Hodgkinson

Liverpool Hospital, Sydney, NSW, Australia

Ernest Butler

40 Monash Medical Centre, Melbourne, Victoria, Australia

Helmut Butzkueven

Department of Neuroscience, Monash Univeristy, Melbourne, Victoria, Australia

Michael Barnett

Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia

Richard Macdonell

Austin Health, Heidelberg, VIC, Australia

Anneke Van Der Walt

Royal Melbourne Hospital, Parkville, VIC, Australia

Charles B Malpas

Department of Neuroscience, Monash University, Melbourne, Victoria, Australia

Pamela McCombe

12Department of Neurology, University of Queensland Centre for Clinical Research and Royal Brisbane and Women`s Hospital, Herston Road, Queensland, Australia

Emmanuelle Leray

Département de Santé Publique, Hôpital Pontchaillou, Rennes, France

Sandra Vukusic

Service de Neurologie A and EDMUS Coordinating Centre, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France; INSERM U 842, Lyon, France; Université de Lyon, Lyon, France; Université Lyon 1, Lyon, France

Izanne Roos

1CORe Unit, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia

Katherine Buzzard

4Neurosciences, Melbourne Health, Melbourne, VIC, Australia

Olga Skibina

4Alfred Health, Melbourne, VIC, Australia